2018 American Transplant Congress
Novel Low Dosing of Rabbit Antithymocyte Globulin Preserves Excellent Outcomes and Improves the Value of Care in Low Risk Renal Transplantation
University of Virginia Health System, Charlottesville, VA.
Elderly and non-sensitized renal transplant patients may benefit from lesser induction immunosuppression. This study evaluates three year clinical outcomes of a low risk renal transplant…2018 American Transplant Congress
Survey of Rabbit Anti-Thymocyte Globulin Usage for Kidney Transplant Induction Therapy in the United States
Background: Rabbit anti-thymocyte globulin (rATG) has become the most widely used induction agent in kidney transplantation (KTx) and has recently received FDA approval for this…2018 American Transplant Congress
The Efficacy and Safety of Rituximab as Induction Therapy in Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials
Objectives. This meta-analysis was undertaken to assess the efficacy and safety of rituximab as induction therapy in kidney transplantation.Methods. OVID, Embase, SCI, PubMed and EBSCO…2018 American Transplant Congress
Rhesus-Specific Anti-Thymocyte Globulin as an Adjuvant to Costimulatory-Blockade-Based Immunotherapy
Background Belatacept targets de novo alloimmune responses with minimal off target effects in renal transplantation, though adjuvant therapy is required to control costimulation-blockade resistant rejection…2018 American Transplant Congress
Individualized Immunosuppression through Risk-Stratification in Renal Transplantation Preserves Excellent Outcomes at Three Years
University of Virginia Health System, Charlottesville, VA.
Risk-stratification of renal transplant recipients based on immunologic risk factors allows for tailored immunosuppression (IS), but long term follow up is limited. This study evaluates…2018 American Transplant Congress
Higher Rates of Rejection in HIV-Infected Kidney Transplant Recipients on Ritonavir-Boosted Protease Inhibitors–Three-Year Follow Up
The Mount Sinai Hospital, New York.
Background: One-year rejection rates in HIV-infected kidney transplant recipients range from 15-40%, compared to overall rejection rates of 10% in HIV-negative patients. Protocols for immunosuppression…2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Liver/Kidney Transplantation
Virginia Commonwealth University, Richmond, VA.
Introduction: There is no data on the risks and benefits of induction immunosuppression in simultaneous liver/kidney transplant (SLKT) patients.Methods: We analyzed all SLKT performed between…2018 American Transplant Congress
Cancer Incidence after Kidney Transplantation in Saudi Arabia, Comparing Different Induction Agents
Kidney and Pancreas Transplantation, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Cancer incidence varies among different induction agents and different population. We aim to compare the incidence of cancer post kidney transplantation among different induction agents…2018 American Transplant Congress
Optimal Protocol for ABO Incompatible Kidney Transplantations: Analysis of 400 Cases in a Single Center Experience
Asan Medical Center, Seoul, Korea.
This study describes the single center experience and long-term results of ABOincompatible kidney transplantation (ABO i KT).Four hundred patientswhoreceived an ABOi KT in the period…2018 American Transplant Congress
Single-Dose Basiliximab Induction in Liver Transplant Recipients with Delayed CNI Initiation
Liver transplant recipients (LTR) with peri-operative renal injury benefit from a delayed CNI protocol using basiliximab (IL2RA) induction to reduce early CNI exposure. Existing literature…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 31
- Next Page »